8.32  -0.14 (-1.65%)		07-18 16:00
Open: 8.445 High: 8.5 Volume: 435,995		Pre. Close: 8.46 Low: 8.1597 Market Cap: 175(M)

Short term
Mid term
Targets	6-month :	10.26	1-year :	11.48
Resists	First :	8.79	Second :	9.82
Pivot price	7.88
Supports	First :	7.11	Second :	5.91
MAs	MA(5) :	7.84	MA(20) :	7.91
	MA(100) :	7.38	MA(250) :	8.84
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	32.1	D(3) :	21.5
RSI	RSI(14): 55.3
52-week	High :	13.88	Low :	4.8

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed below upper band by 26.6%. Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.51 - 8.56	8.56 - 8.6
Low:	8.05 - 8.1	8.1 - 8.15
Close:	8.24 - 8.33	8.33 - 8.41

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Fri, 18 Jul 2025
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance

Thu, 17 Jul 2025
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest

Thu, 17 Jul 2025
Major Breakthrough: Cybin's Depression Drug Enters Global Phase 3 Trial After UK Green Light - Stock Titan

Wed, 16 Jul 2025
Three High-Risk, High-Reward Stocks with Explosive Upside: Rezolve AI, Aurora Innovation, and Cybin Inc. - AInvest

Fri, 11 Jul 2025
Cybin: Upgrade To Hold - But Don't Get Too Carried Away (NYSE:CYBN) - Seeking Alpha

Mon, 30 Jun 2025
Cybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical Progress - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	760 (M)
Shares Float	574 (M)
Held by Insiders	6.9 (%)
Held by Institutions	38.3 (%)
Shares Short	14,900 (K)
Shares Short P.Month	12,740 (K)

EPS	-0.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.37
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.8 %
Return on Equity (ttm)	-49.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-85 (M)
Levered Free Cash Flow	-50 (M)

PE Ratio	-55.47
PEG Ratio	0
Price to Book value	22.48
Price to Sales	0
Price to Cash Flow	-74

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.